antibody

Documents about antibody

• Avelumab for People With Recurrent Respiratory Papillomatosis#812249ClinicalTrials.gov
• Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma#834142ClinicalTrials.gov
• A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer#837697ClinicalTrials.gov
• The Efficacy of Two Potential Diagnostic Assays for Herpes Simplex Keratitis (HSK)#839455ClinicalTrials.gov
• Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)#841838ClinicalTrials.gov
• Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab#843215ClinicalTrials.gov
• Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme#850497ClinicalTrials.gov
• A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)#855296ClinicalTrials.gov
• A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)#860611ClinicalTrials.gov
• Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination#861617ClinicalTrials.gov
• Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112 PET Imaging#868983ClinicalTrials.gov
• High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza#883099ClinicalTrials.gov
• Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin#884790ClinicalTrials.gov
• Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors#195334ClinicalTrials.gov
• Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma#407758ClinicalTrials.gov
• A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors#800662ClinicalTrials.gov
• Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors#803997ClinicalTrials.gov
• Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons#826321ClinicalTrials.gov
• Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma#846912ClinicalTrials.gov
• Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer#850198ClinicalTrials.gov
• A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors#874095ClinicalTrials.gov
• A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma#876937ClinicalTrials.gov
• A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)#887007ClinicalTrials.gov
• Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without HAIC for Unresectable HCC With Portal Vein Tumor Thrombosis#889893ClinicalTrials.gov
• Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates#388254Infoscience
• Cohort Study on Neuroimmune Diseases in the Reproductive Age#806933ClinicalTrials.gov
• Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma#811040ClinicalTrials.gov
• A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma#837128ClinicalTrials.gov
• Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors#843741ClinicalTrials.gov
• To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients#858871ClinicalTrials.gov
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide#861034ClinicalTrials.gov
• A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma#866150ClinicalTrials.gov
• Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study#872027ClinicalTrials.gov
• An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases#875409ClinicalTrials.gov
• An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis#876868ClinicalTrials.gov
• Realistic in Generation of HEp-2 Cell Images Using Latent Diffusion Models: a Multi-center Visual Turing Test#877503ClinicalTrials.gov
• Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma#880178ClinicalTrials.gov
• Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis#883173ClinicalTrials.gov
• A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)#888284ClinicalTrials.gov
• Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer#28400ClinicalTrials.gov
• Caractérisation des propriétés immunomodulatrices des neutrophiles humains dans les infections à VIH-1 et les immunothérapies par anticorps neutralisants à large spectre#195726HAL (France)
• A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.#805713ClinicalTrials.gov
• Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma#808109ClinicalTrials.gov
• A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)#827893ClinicalTrials.gov
• Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer#837252ClinicalTrials.gov
• Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali#848830ClinicalTrials.gov
• Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.#869609ClinicalTrials.gov
• Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine#870185ClinicalTrials.gov
• A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma#875974ClinicalTrials.gov
• A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer#876485ClinicalTrials.gov